T. Rowe Price Associates
DRUG

T. Rowe Price Associates’s Bright Minds Biosciences DRUG Stock Holding History

T. Rowe Price Associates’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$361K Buy
4,947
+2,117
+75% +$170K ﹤0.01% 2587
2025
Q4 		$221K Buy
+2,830
New +$189K ﹤0.01% 2777

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

T. Rowe Price Associates's DRUG Position: Q1 2026 in Review

T. Rowe Price Associates increased its Bright Minds Biosciences (DRUG) stake by 75% in Q1 2026, buying an estimated $170K and bringing the position to 4,947 shares worth $361K. The position accounts for ﹤0.01% of the portfolio, ranked #2587.

T. Rowe Price Associates first reported a position in DRUG in Q4 2025 and has held it in 2 quarters since. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • T. Rowe Price Associates held 4,947 shares of Bright Minds Biosciences worth $361K as of Q1 2026.
  • T. Rowe Price Associates bought 2,117 Bright Minds Biosciences shares in Q1 2026, an estimated $170K.
  • Bright Minds Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2587 holding.
  • T. Rowe Price Associates first reported a position in Bright Minds Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.